Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14299655 | 0.83 | CHRNA7 (0.58) | CHRNA7ROCK1 | |
| SCHEMBL22601562 | 0.81 | HRH4 (0.37) | CHRNA7NR1H2HRH4ROCK1GCK | |
| SCHEMBL25824990 | 0.80 | L3MBTL1 (0.46) | CHRNA7GCK | |
| SCHEMBL25820335 | 0.79 | GFER (0.46) | CHRNA7 | |
| SCHEMBL10920036 | 0.78 | ROCK1 (0.40) | NR1H2NR1H3ROCK1PTGS2 | |
| SCHEMBL3465119 | 0.78 | HRH4 (0.40) | HRH4ROCK1 | |
| SCHEMBL13801171 | 0.74 | UHRF1 (0.48) | ROCK1PTGS2 | |
| SCHEMBL13058477 | 0.73 | CHRNA7 (0.40) | CHRNA7NR1H2NR1H3HRH4PTGS2 | |
| SCHEMBL23015739 | 0.73 | ALDH1A1 (0.43) | CHRNA7 | |
| SCHEMBL5700498 | 0.73 | HRH4 (0.39) | HRH4ROCK1GCKAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541055-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2023-01-03 | — | — | US | disclosed |
| US-20200360384-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-11-19 | — | — | US | disclosed |
| EP-1270582-B1 | TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES | MITSUBISHI RAYON CO (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-6693210-B2 | USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS | MITSUBISHI RAYON CO., LTD. (JP) | 2004-02-17 | — | — | US | disclosed |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | MITSUBISHI RAYON CO., LTD. (JP) | 2003-04-03 | — | — | US | disclosed |
| EP-1270582-A1 | TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE | Mitsubishi Rayon Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541055-B2 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, POLR2E, POLR2H | CHRNA7 4798/4885NR1H2 2001/4885NR1H3 1396/4885 |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | PDCD1LG2, PIK3CA, PDCD1 | CHRNA7 4649/4885NR1H2 3743/4885NR1H3 3648/4885 |
| US-20200360384-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | CHRNA7 4798/4885NR1H2 2001/4885NR1H3 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.